Patient Tools and Information
Voices of MRD: Where We’ve Been, Where We Are Now and Where We’re Going – Audience Questions Answered
On January 27, 2021, the MRD Testing Collaborative hosted a virtual event for patients, advocates, health care professionals and industry leaders about MRD testing. During the event, you asked questions about MRD testing and we answered them!
MRD Testing 101: Definitions to Know
Keeping track of various definitions related to your cancer treatment can be overwhelming. This helpful glossary defines the most common terms related to MRD testing and cancer therapy, to help patients better understand what MRD testing is and how MRD is measured.
Frequently Asked Questions
This frequently asked questions document provides a list of some of the most common MRD testing questions and answers, and is intended to help newly diagnosed blood cancer patients and their families better understand MRD, related terminology, and testing.
Questions to Ask Your Doctor Worksheet
This worksheet outlines questions about MRD testing that can help guide discussions about treatment plans between patients and their doctor or specialist. The worksheet also provides space for patients to record answers and notes based on their discussions, and is available both as a PDF and a Word document that can be filled out electronically.
Questions to Ask Your Doctor Reminder Card
Heading to an appointment with a doctor can be overwhelming, especially if you do not know what questions to ask. This palm-sized card is perfect to keep with you on-the-go, and outlines questions about MRD testing that can help guide discussions about treatment plans between patients and their doctor or specialist.
About the MRD Testing Collaborative
The mission and purpose of the MRD Testing Collaborative is to inform patients and health care professionals on personalized testing in the blood cancer community, with a focus on minimal residual disease (MRD). The Collaborative also brings together like-minded patient advocacy stakeholders and industry partners to collectively address blood cancer patient needs regarding testing.